Company profile: Immunitas Therapeutics
1.1 - Company Overview
Company description
- Provider of single-cell genomics and machine learning-based drug discovery to modulate oncology targets; antibody discovery and engineering; biomarker development; and IMT-009, an immuno-oncology a-CD161 mAb in clinical evaluation for solid tumors and hematological malignancies.
Products and services
- Single-cell genomics-based drug discovery: Architects a machine-learning–driven process combining single-cell genomics to identify immune cell populations for oncology target modulation
- Antibody discovery and engineering: Engineers custom-engineered therapeutic antibodies using internal expertise and parallel discovery efforts to discover and advance candidates that modulate oncology targets
- IMT-009 (a-CD161 mAb): Delivers a clinical-stage immuno-oncology, antibody-based therapeutic targeting CD161, currently being evaluated for potential efficacy in solid tumors and hematological malignancies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunitas Therapeutics
AB Science
HQ: France
Website
- Description: Provider of pharmaceutical therapies specializing in tyrosine kinase inhibitors, including Masitinib being developed for ALS, indolent systemic mastocytosis, severe asthma, progressive MS, first-line pancreatic cancer with pain, Alzheimer’s disease, and metastatic castrate-resistant prostate cancer, and AB8939, a microtubule destabilizer being developed for acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AB Science company profile →
Blue Earth Diagnostics
HQ: United Kingdom
Website
- Description: Provider of molecular PET imaging agents and technologies for cancer diagnosis, developing and commercialising radiopharmaceuticals addressing high unmet medical needs. Offerings include Axumin (fluciclovine F 18) for detecting recurrent prostate cancer, POSLUMA (flotufolastat F 18) Injection for detecting prostate cancer, FAP-targeted PET technology for multiple solid tumors, and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blue Earth Diagnostics company profile →
Prelude Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule cancer therapies and precision antibody-drug conjugates, including PRT3789, a selective SMARCA2 degrader for SMARCA4-deficient tumors; PRT2527, a highly selective CDK9 inhibitor in Phase 1; PRT3645, a next-generation CDK4/6 inhibitor in preclinical studies; and ADCs developed with AbCellera.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prelude Therapeutics company profile →
Quantum Surgical
HQ: France
Website
- Description: Provider of robotic-assisted interventional oncology solutions for minimally invasive liver cancer treatment, including Epione for planning, targeting, delivery and confirmation of tumor ablation; CT/MRI fusion-based multimodal planning; real-time respiratory monitoring; post-ablation margin verification; and robotic guidance with navigation and haptics (6 DOF) for precise targeting and safe needle release.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantum Surgical company profile →
Halozyme
HQ: United States
Website
- Description: Provider of extracellular matrix-targeting products and drug delivery technologies, including ENHANZE to enable subcutaneous delivery and reduce administration time vs hours-long IV infusions; HYLENEX recombinant hyaluronidase to aid dispersion and absorption of injected drugs/fluids; XYOSTED testosterone enanthate for replacement therapy; and auto-injector platforms for subcutaneous/intramuscular use, with a partner pipeline in five approved therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Halozyme company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunitas Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunitas Therapeutics
2.2 - Growth funds investing in similar companies to Immunitas Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunitas Therapeutics
4.2 - Public trading comparable groups for Immunitas Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →